EloPd for the treatment of RRMM: Real-world efficacy and safety data

The combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) was investigated as part of the ELOQUENT-3 (NCT02654132) trial leading to its approval in patients with relapsed/refractory multiple myeloma (RRMM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor.¹

Here, we summarize a publication by Gentile et al.¹ in Haematologica on real-world experiences and outcomes in patients with RRMM treated with EloPd compared with the clinical trial data from ELOQUENT-3.

Study design¹

• Data was collected from 200 patients with RRMM treated with EloPd across multiple Italian centers outside of clinical trials
• Outcome data was compared with the ELOQUENT-3 trial data to establish real-world EloPd efficacy and safety
• All patients were treated with EloPd according to the marketing approval

Key findings¹

• The overall response rate was 55.4% (Figure 1) with a median time to response of 1.8 months, comparable with ELOQUENT-3 at 53%
• Median progression-free survival (PFS) was 7 months, shorter than what was observed in ELOQUENT-3 which was 10.3 months
• At a median follow-up of 9 months, 126 patients had stopped treatment with EloPd; 88.9% of these were due to disease progression
• Median overall survival was observed at 17.5 months compared with 29.8 months observed in ELOQUENT-3
• The characteristic associated with the poorest 12-month PFS rate was an International Staging System Stage III at 24.2% and a hazard ratio of 2.55 (Figure 2)
• Adverse events and toxicity profiles were comparable with ELOQUENT-3, and no significant differences were observed depending on age

CR, complete response; ORR, overall response rate; PR, partial response; VGPR, very good PR.
*Data from Gentile, et al.¹

ASCT, autologous stem cell transplant; CrCL, creatinine clearance; ISS, International Staging System; LOT, line of therapy; mo, month; OS, overall survival; PFS, progression-free survival.
*Data from Gentile, et al.¹

 

Key learnings

Real world data in patients with RRMM treated with EloPd is comparable with ELOQUENT-3 trial data. Few key outcomes, such as PFS, differed from clinical trial data. This is likely attributed to stringent inclusion and exclusion criteria in clinical trials leading to a non-representative population. Results from this retrospective trial provide additional evidence to support the use of EloPd in patients with RRMM who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor.